Orgenesis Stock Current Asset
ORGSDelisted Stock | USD 1.22 0.31 20.26% |
Orgenesis fundamentals help investors to digest information that contributes to Orgenesis' financial success or failures. It also enables traders to predict the movement of Orgenesis OTC Stock. The fundamental analysis module provides a way to measure Orgenesis' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Orgenesis otc stock.
Orgenesis |
Orgenesis OTC Stock Current Asset Analysis
Orgenesis' Current Asset is all of the company's assets that can be used to pay off current liabilities within the current fiscal period or over the next 12 months. Current Asset includes cash or cash equivalents, accounts receivable, short-term investments, and the portion of prepaid liabilities which will be paid within the next 12 months. Because these assets are easily turned into cash, they are sometimes referred to as liquid assets.
Current Orgenesis Current Asset | 5.29 M |
Most of Orgenesis' fundamental indicators, such as Current Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Orgenesis is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Current Asset is important to company's creditors and private equity firms as they will often be interested in how much that company has in current assets since these assets can be easily liquidated in case the company goes bankrupt. However, it is usually not enough to know if a company is in good shape just based on current asset alone; the amount of current liabilities should always be considered.
CompetitionIn accordance with the recently published financial statements, Orgenesis has a Current Asset of 5.29 M. This is 99.75% lower than that of the Biotechnology sector and 99.5% lower than that of the Health Care industry. The current asset for all United States stocks is 99.94% higher than that of the company.
Orgenesis Current Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Orgenesis' direct or indirect competition against its Current Asset to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Orgenesis could also be used in its relative valuation, which is a method of valuing Orgenesis by comparing valuation metrics of similar companies.Orgenesis is currently under evaluation in current asset category among its peers.
Orgenesis Fundamentals
Return On Equity | -7.27 | ||||
Return On Asset | -0.3 | ||||
Operating Margin | (16.54) % | ||||
Current Valuation | 23.01 M | ||||
Shares Outstanding | 4.77 M | ||||
Shares Owned By Insiders | 21.16 % | ||||
Shares Owned By Institutions | 4.54 % | ||||
Number Of Shares Shorted | 56.25 K | ||||
Price To Earning | 7.52 X | ||||
Price To Book | 1.26 X | ||||
Price To Sales | 15.21 X | ||||
Revenue | 530 K | ||||
Gross Profit | 36.02 M | ||||
EBITDA | (54.07 M) | ||||
Net Income | (64.92 M) | ||||
Cash And Equivalents | 2.3 M | ||||
Cash Per Share | 0.09 X | ||||
Total Debt | 22.62 M | ||||
Debt To Equity | 0.64 % | ||||
Current Ratio | 1.57 X | ||||
Book Value Per Share | (3.30) X | ||||
Cash Flow From Operations | (14.84 M) | ||||
Short Ratio | 2.39 X | ||||
Earnings Per Share | (8.00) X | ||||
Target Price | 6.0 | ||||
Number Of Employees | 146 | ||||
Beta | 1.21 | ||||
Market Capitalization | 10.07 M | ||||
Total Asset | 14.55 M | ||||
Retained Earnings | (176.62 M) | ||||
Working Capital | (12.33 M) | ||||
Current Asset | 5.29 M | ||||
Current Liabilities | 14.92 M | ||||
Net Asset | 14.55 M |
About Orgenesis Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Orgenesis's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Orgenesis using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Orgenesis based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in price. Note that the Orgenesis information on this page should be used as a complementary analysis to other Orgenesis' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Other Consideration for investing in Orgenesis OTC Stock
If you are still planning to invest in Orgenesis check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Orgenesis' history and understand the potential risks before investing.
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
CEOs Directory Screen CEOs from public companies around the world | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |